Cargando…
Targeting GPCRs to treat cardiac fibrosis
Cardiac fibrosis occurs ubiquitously in ischemic heart failure, genetic cardiomyopathies, diabetes mellitus, and aging. It triggers myocardial stiffness, which impairs cardiac function, ultimately progressing to end-stage heart failure and increased mortality. Although several targets for anti-fibro...
Autores principales: | Zhang, Hao, Ren, Lu, Shivnaraine, Rabindra Vishwadev |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582444/ https://www.ncbi.nlm.nih.gov/pubmed/36277752 http://dx.doi.org/10.3389/fcvm.2022.1011176 |
Ejemplares similares
-
Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
por: Audebrand, Anais, et al.
Publicado: (2020) -
Transcriptome and proteome profiling of activated cardiac fibroblasts supports target prioritization in cardiac fibrosis
por: Moita, Maria Raquel, et al.
Publicado: (2022) -
Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target
por: Schimmel, Katharina, et al.
Publicado: (2022) -
Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling
por: Parichatikanond, Warisara, et al.
Publicado: (2020) -
TRPC3 Channels in Cardiac Fibrosis
por: Numaga-Tomita, Takuro, et al.
Publicado: (2017)